Acticor Biotech

MABDESIGN MEMBER

About us

Acticor Biotech is a spin-off of Inserm (French National Institute of Health and Medical Research). Founded in late 2013 it is dedicated to the development of an new antithrombotic drug for ischemic stroke. The product is a humanized fragment (Fab) of antibody directed against a new target of major interest: the platelet glycoprotein VI (GPVI).

Field of application
  • antibodies
Therapeutic application
  • cardiology

Expertise

  • Assay development in in-vitro & in-vivo models
  • Master Cell Bank
  • Production
  • Characterization
  • Storage
  • Phase I
  • Phase II

Category

  • Therapeutic product

Contact